Armata Pharmaceuticals Inc (NASDAQ: ARMP) is a clinical-stage biopharmaceutical company focused on developing bacteriophage-based therapeutics targeting antibiotic-resistant bacterial infections. The company has no commercialized products as of the FY2025 10-K filed March 25, 2026, and generates no product revenue. Armata is developing candidates targeting infections including Staphylococcus aureus bacteremia, prosthetic joint infections, and wound infections, areas where drug-resistant strains have outpaced existing treatments such as vancomycin and daptomycin. The company operates a Los Angeles production facility maintained under current Good Manufacturing Practices. Armata relies on third-party contract research organizations and manufacturers for portions of its development work. Its capital structure includes a convertible loan and term debt as of December 31, 2025, with no dividend payments. IP protection relies on patents, trade secrets, and data exclusivity tied to biologics regulatory pathways, including potential orphan drug and pediatric use extensions.

Revenue model

No product revenue as of FY2025. The company is pre-commercialization and funds operations through equity and debt financing, including a convertible loan and term debt visible on the December 31, 2025 balance sheet. Future revenue, if any, would depend on regulatory approval and third-party payor reimbursement from Medicare, Medicaid, private insurers, and managed-care plans.

Products and services

Bacteriophage-based therapeutic product candidates targeting antibiotic-resistant bacterial infections, specifically Staphylococcus aureus bacteremia, prosthetic joint infections, and wound infections. No products are FDA-approved or commercialized as of the FY2025 10-K filing.

Customers and end markets

Target end markets include hospital and institutional settings treating patients with S. aureus bacteremia and prosthetic joint infections. S. aureus PJI-related revision surgeries in the United States and EU Five were approximately 70,000 in 2020, projected to reach 144,000 by 2040. The United States accounted for 61% of PJI-related revision surgeries in 2020, estimated at $150,000 each. No commercial customers exist as of the FY2025 filing.

Value-chain role

Drug developer and manufacturer. Armata conducts preclinical and clinical development internally and through contract research organizations, and operates its own Los Angeles cGMP-compliant production facility for bacteriophage candidates. The company is upstream of commercialization and relies on regulatory approval before any sales activity.

Geographic exposure

Primary operations in Los Angeles, California. Regulatory focus is on FDA approval in the United States. The filing notes subject to foreign regulatory requirements for any future international clinical trials or marketing, but no international commercial operations exist as of the FY2025 10-K.

Competitors

Vancomycin (standard of care antibiotic), Daptomycin (FDA-approved 2006 for S. aureus bacteremia), Zevtera (ceftobiprole medocaril sodium, FDA-approved April 2024 for S. aureus bacteremia)

Source: SEC 10-K, filed 2026-03-25

Industry: Biological Products, (No Diagnostic Substances) Peers: Savara Inc Akouos, Inc. Ardelyx Inc CHIMERIX INC LENZ Therapeutics Inc Oyster Point Pharma, Inc. Viracta Therapeutics, Inc. Verastem Inc